# NCT03471260 (NCT03471260)

> Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03471260
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Acute Myeloid Leukemia; Hematopoietic and Lymphoid System Neoplasm; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
- Interventions: Azacitidine; Ivosidenib; Venetoclax
- Enrollment: 96
- Primary outcome: Overall response rate (ORR)
- Primary outcome: Incidence of adverse events
- Primary outcome: Dose-limiting toxicity

## Indexed commentary on NCT03471260 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03471260